Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens

被引:133
作者
Iwasaki, Masashi [3 ]
Tanaka, Yoshimasa [1 ,2 ]
Kobayashi, Hirohito [4 ]
Murata-Hirai, Kaoru
Miyabe, Hideto
Sugie, Tomoharu [5 ]
Toi, Masakazu [5 ]
Minato, Nagahiro [1 ,3 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto, Japan
[3] Kyoto Univ, Grad Sch Biostudies, Lab Immunol & Cell Biol, Kyoto, Japan
[4] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan
关键词
gamma delta T cells; Phosphoantigen; PD-1; PD-L1; Tumor; NONPEPTIDE ANTIGENS; DILATED CARDIOMYOPATHY; MEDIATED RECOGNITION; ZOLEDRONIC ACID; TUMOR-CELLS; IN-VIVO; IMMUNOTHERAPY; RECEPTOR; B7-H1; PATHWAY;
D O I
10.1002/eji.201040959
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed cell death-1 (PD-1) is an inhibitory receptor and plays an important role in the regulation of alpha beta T cells. Little is known, however, about the role of PD-1 in gamma delta T cells. In this study, we investigated the expression and function of PD-1 in human gamma delta T cells. Expression of PD-1 was rapidly induced in primary gamma delta T cells following antigenic stimulation, and the PD-1(+) gamma delta T cells produced IL-2. When PD-1(+) gamma delta T cells were stimulated with Daudi cells with and without programmed cell death ligand-1 (PD-L1) expression, the levels of IFN-gamma production and cytotoxicity in response to PD-L1(+) Daudi cells were diminished compared to the levels seen in response to PD-L1(-) Daudi cells. The attenuated effector functions were reversed by anti-PD-L1 mAb. When PD-L1(+) gamma delta T cells were challenged by PD-L1(+) tumors pretreated with zoledronate (Zol), which induced gamma delta TCR-mediated signaling, the resulting reduction in cytokine production was only slight to moderate compared to the reduction seen when PD-L1(+) gamma delta T cells were challenged by PD-L1(-) tumors. In addition, cytotoxic activity of PD-L1(+) gamma delta T cells against Zol-treated PD-L1(+) tumors was comparable to that against Zol-treated PD-L1(-) tumors. These results suggest that TCR triggering may partially overcome the inhibitory effect of PD-1 in gamma delta T cells.
引用
收藏
页码:345 / 355
页数:11
相关论文
共 50 条
[41]   Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice [J].
Okazaki, T ;
Tanaka, Y ;
Nishio, R ;
Mitsuiye, T ;
Mizoguchi, A ;
Wang, J ;
Ishida, M ;
Hiai, H ;
Matsumori, A ;
Minato, N ;
Honjo, T .
NATURE MEDICINE, 2003, 9 (12) :1477-1483
[42]   PD-1 and PD-1 ligands: from discovery to clinical application [J].
Okazaki, Taku ;
Honjo, Tasuku .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (07) :813-824
[43]   Studies on the nonmevalonate terpene biosynthetic pathway:: Metabolic role of IspH (LytB) protein [J].
Rohdich, F ;
Hecht, S ;
Gärtner, K ;
Adam, P ;
Krieger, C ;
Amslinger, S ;
Arigoni, D ;
Bacher, A ;
Eisenreich, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1158-1163
[44]   In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients [J].
Santini, Daniele ;
Martini, Federico ;
Fratto, Maria Elisabetta ;
Galluzzo, Sara ;
Vincenzi, Bruno ;
Agrati, Chiara ;
Turchi, Federica ;
Piacentini, Paola ;
Rocci, Laura ;
Manavalan, John S. ;
Tonini, Giuseppe ;
Poccia, Fabrizio .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) :31-38
[45]   NATURAL AND SYNTHETIC NONPEPTIDE ANTIGENS RECOGNIZED BY HUMAN GAMMA-DELTA T-CELLS [J].
TANAKA, Y ;
MORITA, CT ;
TANAKA, Y ;
NIEVES, E ;
BRENNER, MB ;
BLOOM, BR .
NATURE, 1995, 375 (6527) :155-158
[46]   NONPEPTIDE LIGANDS FOR HUMAN GAMMA-DELTA T-CELLS [J].
TANAKA, Y ;
SANO, S ;
NIEVES, E ;
DELIBERO, G ;
ROSA, D ;
MODLIN, RL ;
BRENNER, MB ;
BLOOM, BR ;
MORITA, CT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8175-8179
[47]   Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function [J].
Terawaki, Selgo ;
Tanaka, Yoshimasa ;
Nagakura, Tornokazu ;
Hayashi, Tarnon ;
Shibayama, Shiro ;
Muroi, Kaori ;
Okazaki, Taku ;
Mikami, Bunzo ;
Garboczi, David N. ;
Honjo, Tasuku ;
Minato, Nagahiro .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (07) :881-890
[48]   Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up [J].
Thompson, RH ;
Kuntz, SM ;
Leibovich, BC ;
Dong, HD ;
Lohse, CM ;
Webster, WS ;
Sengupta, S ;
Frank, I ;
Parker, AS ;
Zincke, H ;
Blute, ML ;
Sebo, TJ ;
Cheville, JC ;
Kwon, ED .
CANCER RESEARCH, 2006, 66 (07) :3381-3385
[49]   Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates [J].
van Beek, E ;
Pieterman, E ;
Cohen, L ;
Löwik, C ;
Papapoulos, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 264 (01) :108-111
[50]   B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders [J].
Wilcox, Ryan A. ;
Feldman, Andrew L. ;
Wada, David A. ;
Yang, Zhi-Zhang ;
Comfere, Nneka I. ;
Dong, Haidong ;
Kwon, Eugene D. ;
Novak, Anne J. ;
Markovic, Svetomir N. ;
Pittelkow, Mark R. ;
Witzig, Thomas E. ;
Ansell, Stephen M. .
BLOOD, 2009, 114 (10) :2149-2158